Article | April 19, 2022

Off-The-Shelf Vs. Novel Devices: Considerations When Selecting A Drug Delivery System

By Scott Arra, Sr. Director, Business Development, and Evan Edwards, Chief Development Officer, Kymanox Corporation, Morrisville, North Carolina

GettyImages-1337453095-doctor-patient

Pharmaceutical and biotechnology companies continue to develop drug and biologic products that require alternative routes of administration, such as nasal delivery devices, auto-injectors, pen-injectors, and on-body / wearable delivery systems. Companies must consider a multitude of factors when determining the right delivery system for their drug. Furthermore, when life science companies introduce a change in the drug or in the device for on-the-market products, there are additional factors to evaluate.

Currently, companies have two options for drug delivery technologies: 1) selecting ‘off-the-shelf’ drug delivery systems, and 2) developing novel or unique devices. Whether a company is bringing a novel therapy to market or altering current devices for lifecycle management, companies must review their options and determine the best selection for administration without effecting drug efficacy, quality, and safety.

This article explores challenges with platform selection and the advantages and disadvantages of off-the-shelf and novel devices.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: